TGOD.TO Green Organic Dutchman TSX 13 Feb after-hours: 19,704,275 traded monitor

A heavy after-hours volume of 19,704,275 shares put TGOD.TO stock in focus on 13 Feb 2026 as traders reacted to intraday swings. The Green Organic Dutchman Holdings Ltd. (TGOD.TO) closed at C$0.17 in the TSX after-hours session, matching the previous close and showing a day range between C$0.165 and C$0.22. This most-active trade pattern comes with a relative volume of 12.43, signalling far higher participation than normal. We outline price action, valuation, technicals, and Meyka AI model forecasts to frame near-term market implications for Canadian healthcare investors.

TGOD.TO stock price and volume action

TGOD.TO stock closed the regular session at C$0.17 and recorded an after-hours range that matched intraday volatility, with a day high of C$0.22 and a day low of C$0.165. Volume for the session hit 19,704,275 versus an average volume of 1,585,835, producing a relative volume of 12.43, a clear marker that this name was among the most active on the TSX in after-hours trading.

Valuation and recent financials for The Green Organic Dutchman (TGOD.TO)

On trailing metrics the company reports EPS -0.23 and an operating PE of -0.74, reflecting ongoing losses. Price-to-book stands at 0.45 while enterprise value is approximately CAD 35,113,000.00. Revenue per share is 0.06 and book value per share is 0.38, which implies value investors see tangible assets behind the low share price even as margins remain negative.

Technicals, liquidity and trading context for TGOD.TO stock

Short-term averages show a 50-day price average of C$0.24 and a 200-day of C$0.31, both above the current price, indicating the stock trades below medium- and long-term trends. Average true range is 0.05, and the stock shows large inventory and receivables cycles versus peers. With shares trading at C$0.17 and active liquidity this session, intraday traders should note the thin formal market-cap reporting and elevated volatility.

Meyka AI grade and model forecast for TGOD.TO

Meyka AI rates TGOD.TO with a score of 62.86 out of 100 — Grade B, suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a near-term monthly price of C$0.17, matching the current price and implying 0.00% immediate upside; forecasts are model-based projections and not guarantees.

Risks, catalysts and sector backdrop for TGOD.TO stock

TGOD.TO operates in the Healthcare sector (Drug Manufacturers – Specialty & Generic) where year-to-date sector performance is weak, adding headwinds to capital access. Key risks include continued negative earnings, stretched operating cash flow metrics, and regulatory or retail demand shifts. Catalysts that could change the outlook include improved quarterly revenue growth, margin recovery, or balance-sheet strengthening via strategic financing.

Analyst stance, price targets and trading strategy for TGOD.TO

There is limited published analyst consensus; we present scenario price targets: base-case C$0.25 (implied upside 47.06%), bull C$0.50 (implied upside 194.12%), and bear C$0.10 (implied downside -41.18%). Traders looking at TGOD.TO stock should weigh high intraday liquidity against fundamental weakness, and use tight risk controls when position sizing in CAD.

Final Thoughts

TGOD.TO stock shows classic most-active session behavior: heavy volume, wide intraday range, and a price that sits below both 50- and 200-day averages. At C$0.17, the market is pricing in continued recovery risk while tangible book value and low price-to-book provide a value signal for longer-term investors willing to accept execution risk. Meyka AI’s forecast model projects C$0.17 in the near term, implying 0.00% upside from the current price; model-based projections are not guarantees. For a practical frame: a base-case price target of C$0.25 implies 47.06% upside, while a bear target of C$0.10 implies -41.18% downside. Given negative EPS and thin formal market-cap reporting, discipline on position size, stop levels, and monitoring of corporate updates is essential. Meyka AI provides this AI-powered market analysis platform view to help investors balance active-trader signals with financial fundamentals in the Canadian TSX healthcare context.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.